Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition

Reuters

2025/11/17

Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition

Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584699456"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584699456\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584699456?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 07:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584699456","market":"fut","top_or_hot":-1,"title":"Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 07:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251116:nNDLccn5L4:1","article_id":"2584699456","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584699456","pubTimestamp":1763334212,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for information","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","RGT.AU":"Argent BioPharma Limited"},"translate_title":"Argent Biopharma从C/M Capital获得1100万美元融资用于战略收购","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGT.AU":0.9},"content_text":"Argent Biopharma Secures A$11m Financing Facility from C/M Capital for Strategic Acquisition\n    \n\n        Argent Biopharma Ltd. has secured a new A$11 million financing facility with US-based venture fund C/M Capital to support the completion of its strategic acquisition of AusCann Group assets and to finance future growth strategies. The agreement, involving two institutional funds managed by C/M Capital Partners, LP, provides an immediate A$3 million drawdown for working capital and the acquisition. Additionally, Argent has executed a deed of variation with Mercer Street Global Fund LLC to amend the terms of existing convertible notes, subject to shareholder approval at the 2025 Annual General Meeting. This funding positions Argent to complete its acquisition, strengthen its operational and financial base, and accelerate its plans for a dual listing on a major US stock exchange.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Argent Biopharma Ltd. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}